[1]
Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Recurrent urinary tract infections in women. International urogynecology journal. 2015 Jun:26(6):795-804. doi: 10.1007/s00192-014-2569-5. Epub 2014 Nov 20
[PubMed PMID: 25410372]
[2]
Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. The American journal of medicine. 2002 Jul 8:113 Suppl 1A():5S-13S
[PubMed PMID: 12113866]
[3]
Anger J, Lee U, Ackerman AL, Chou R, Chughtai B, Clemens JQ, Hickling D, Kapoor A, Kenton KS, Kaufman MR, Rondanina MA, Stapleton A, Stothers L, Chai TC. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. The Journal of urology. 2019 Aug:202(2):282-289. doi: 10.1097/JU.0000000000000296. Epub 2019 Jul 8
[PubMed PMID: 31042112]
[4]
Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. The New England journal of medicine. 2013 Nov 14:369(20):1883-91. doi: 10.1056/NEJMoa1302186. Epub
[PubMed PMID: 24224622]
[5]
Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014 Feb 26:311(8):844-54. doi: 10.1001/jama.2014.303. Epub
[PubMed PMID: 24570248]
[7]
Lo E, Nicolle LE, Coffin SE, Gould C, Maragakis LL, Meddings J, Pegues DA, Pettis AM, Saint S, Yokoe DS. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infection control and hospital epidemiology. 2014 May:35(5):464-79. doi: 10.1086/675718. Epub
[PubMed PMID: 24709715]
[8]
Larcombe J. Urinary tract infection in children: recurrent infections. BMJ clinical evidence. 2015 Jun 12:2015():. pii: 0306. Epub 2015 Jun 12
[PubMed PMID: 26067232]
[10]
Meštrović T, Matijašić M, Perić M, Čipčić Paljetak H, Barešić A, Verbanac D. The Role of Gut, Vaginal, and Urinary Microbiome in Urinary Tract Infections: From Bench to Bedside. Diagnostics (Basel, Switzerland). 2020 Dec 22:11(1):. doi: 10.3390/diagnostics11010007. Epub 2020 Dec 22
[PubMed PMID: 33375202]
[11]
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Mar 1:52(5):e103-20. doi: 10.1093/cid/ciq257. Epub
[PubMed PMID: 21292654]
Level 1 (high-level) evidence
[12]
Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1994 Aug:19(2):274-8
[PubMed PMID: 7986899]
[13]
Scholes D, Hawn TR, Roberts PL, Li SS, Stapleton AE, Zhao LP, Stamm WE, Hooton TM. Family history and risk of recurrent cystitis and pyelonephritis in women. The Journal of urology. 2010 Aug:184(2):564-9. doi: 10.1016/j.juro.2010.03.139. Epub 2010 Jun 19
[PubMed PMID: 20639019]
[14]
Zhong YH, Fang Y, Zhou JZ, Tang Y, Gong SM, Ding XQ. Effectiveness and safety of patient initiated single-dose versus continuous low-dose antibiotic prophylaxis for recurrent urinary tract infections in postmenopausal women: a randomized controlled study. The Journal of international medical research. 2011:39(6):2335-43
[PubMed PMID: 22289552]
Level 1 (high-level) evidence
[15]
Glover M, Moreira CG, Sperandio V, Zimmern P. Recurrent urinary tract infections in healthy and nonpregnant women. Urological science. 2014 Mar:25(1):1-8
[PubMed PMID: 27499825]
[16]
Bent S, Nallamothu BK, Simel DL, Fihn SD, Saint S. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002 May 22-29:287(20):2701-10
[PubMed PMID: 12020306]
[17]
Pat JJ, Steffens MG, Witte LPW, Marcelissen TAT, Blanker MH. Comparison of the diagnostic yield of routine versus indicated flowmetry, ultrasound and cystoscopy in women with recurrent urinary tract infections. International urogynecology journal. 2022 Aug:33(8):2283-2289. doi: 10.1007/s00192-021-04871-2. Epub 2021 Jun 14
[PubMed PMID: 34125244]
[18]
Stein R, Dogan HS, Hoebeke P, Kočvara R, Nijman RJ, Radmayr C, Tekgül S, European Association of Urology, European Society for Pediatric Urology. Urinary tract infections in children: EAU/ESPU guidelines. European urology. 2015 Mar:67(3):546-58. doi: 10.1016/j.eururo.2014.11.007. Epub 2014 Dec 2
[PubMed PMID: 25477258]
[19]
Bremnor JD, Sadovsky R. Evaluation of dysuria in adults. American family physician. 2002 Apr 15:65(8):1589-96
[PubMed PMID: 11989635]
[22]
Lawrentschuk N, Ooi J, Pang A, Naidu KS, Bolton DM. Cystoscopy in women with recurrent urinary tract infection. International journal of urology : official journal of the Japanese Urological Association. 2006 Apr:13(4):350-3
[PubMed PMID: 16734849]
[23]
Arnold JJ, Hehn LE, Klein DA. Common Questions About Recurrent Urinary Tract Infections in Women. American family physician. 2016 Apr 1:93(7):560-9
[PubMed PMID: 27035041]
[24]
Siff LN, Unger CA, Jelovsek JE, Paraiso MF, Ridgeway BM, Barber MD. Assessing ureteral patency using 10% dextrose cystoscopy fluid: evaluation of urinary tract infection rates. American journal of obstetrics and gynecology. 2016 Jul:215(1):74.e1-6. doi: 10.1016/j.ajog.2016.02.006. Epub 2016 Feb 12
[PubMed PMID: 26875949]
[25]
Barry HC, Hickner J, Ebell MH, Ettenhofer T. A randomized controlled trial of telephone management of suspected urinary tract infections in women. The Journal of family practice. 2001 Jul:50(7):589-94
[PubMed PMID: 11485707]
Level 1 (high-level) evidence
[26]
Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. International journal of antimicrobial agents. 2003 Oct:22 Suppl 2():73-8
[PubMed PMID: 14527775]
[27]
Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA, NAUTICA Group, Hoban DJ. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). International journal of antimicrobial agents. 2006 Jun:27(6):468-75
[PubMed PMID: 16713191]
[28]
Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. International journal of antimicrobial agents. 2003 Oct:22 Suppl 2():49-52
[PubMed PMID: 14527771]
[29]
Yamashita K, Ishiyama Y, Yoshino M, Tachibana H, Toki D, Konda R, Kondo T. Urinary Tract Infection in Hemodialysis-Dependent End-Stage Renal Disease Patients. Research and reports in urology. 2022:14():7-15. doi: 10.2147/RRU.S346020. Epub 2022 Jan 16
[PubMed PMID: 35079597]
[30]
Behzadi P, Urbán E, Matuz M, Benkő R, Gajdács M. The Role of Gram-Negative Bacteria in Urinary Tract Infections: Current Concepts and Therapeutic Options. Advances in experimental medicine and biology. 2021:1323():35-69. doi: 10.1007/5584_2020_566. Epub
[PubMed PMID: 32596751]
Level 3 (low-level) evidence
[31]
Bono MJ, Leslie SW, Reygaert WC, Doerr C. Uncomplicated Urinary Tract Infections (Nursing). StatPearls. 2024 Jan:():
[PubMed PMID: 33760460]
[32]
Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. The Journal of infectious diseases. 2000 Oct:182(4):1177-82
[PubMed PMID: 10979915]
[33]
Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clinical therapeutics. 2008 Mar:30(3):453-68. doi: 10.1016/j.clinthera.2008.03.013. Epub
[PubMed PMID: 18405785]
[34]
Barea BM, Veeratterapillay R, Harding C. Nonantibiotic treatments for urinary cystitis: an update. Current opinion in urology. 2020 Nov:30(6):845-852. doi: 10.1097/MOU.0000000000000821. Epub
[PubMed PMID: 33009152]
Level 3 (low-level) evidence
[35]
Song G, Koro M, Leung V, Loh G. Literature Review of Ascorbic Acid, Cranberry, and D-mannose for Urinary Tract Infection Prophylaxis in Older People. The Senior care pharmacist. 2023 Aug 1:38(8):315-328. doi: 10.4140/TCP.n.2023.315. Epub
[PubMed PMID: 37496168]
[36]
Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World journal of urology. 2014 Feb:32(1):79-84. doi: 10.1007/s00345-013-1091-6. Epub 2013 Apr 30
[PubMed PMID: 23633128]
Level 1 (high-level) evidence
[37]
Hayward G, Mort S, Hay AD, Moore M, Thomas NPB, Cook J, Robinson J, Williams N, Maeder N, Edeson R, Franssen M, Grabey J, Glogowska M, Yang Y, Allen J, Butler CC. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA internal medicine. 2024 Apr 8:():. doi: 10.1001/jamainternmed.2024.0264. Epub 2024 Apr 8
[PubMed PMID: 38587819]
Level 1 (high-level) evidence
[38]
Cooper TE, Teng C, Howell M, Teixeira-Pinto A, Jaure A, Wong G. D-mannose for preventing and treating urinary tract infections. The Cochrane database of systematic reviews. 2022 Aug 30:8(8):CD013608. doi: 10.1002/14651858.CD013608.pub2. Epub 2022 Aug 30
[PubMed PMID: 36041061]
Level 1 (high-level) evidence
[39]
Wagenlehner F, Lorenz H, Ewald O, Gerke P. Why d-Mannose May Be as Efficient as Antibiotics in the Treatment of Acute Uncomplicated Lower Urinary Tract Infections-Preliminary Considerations and Conclusions from a Non-Interventional Study. Antibiotics (Basel, Switzerland). 2022 Feb 25:11(3):. doi: 10.3390/antibiotics11030314. Epub 2022 Feb 25
[PubMed PMID: 35326777]
[40]
Li JM, Cosler LE, Harausz EP, Myers CE, Kufel WD. Methenamine for urinary tract infection prophylaxis: A systematic review. Pharmacotherapy. 2024 Feb:44(2):197-206. doi: 10.1002/phar.2895. Epub 2023 Nov 28
[PubMed PMID: 37986168]
Level 1 (high-level) evidence
[41]
Stair SL, Palmer CJ, Lee UJ. Evidence-based review of nonantibiotic urinary tract infection prevention strategies for women: a patient-centered approach. Current opinion in urology. 2023 May 1:33(3):187-192. doi: 10.1097/MOU.0000000000001082. Epub 2023 Mar 2
[PubMed PMID: 36862100]
Level 3 (low-level) evidence
[42]
Venturini S, Reffo I, Avolio M, Basaglia G, Del Fabro G, Callegari A, Tonizzo M, Sabena A, Rondinella S, Mancini W, Conte C, Crapis M. The Management of Recurrent Urinary Tract Infection: Non-Antibiotic Bundle Treatment. Probiotics and antimicrobial proteins. 2023 Aug 16:():. doi: 10.1007/s12602-023-10141-y. Epub 2023 Aug 16
[PubMed PMID: 37584833]
[43]
Chen YC, Lee WC, Chuang YC. Emerging Non-Antibiotic Options Targeting Uropathogenic Mechanisms for Recurrent Uncomplicated Urinary Tract Infection. International journal of molecular sciences. 2023 Apr 11:24(8):. doi: 10.3390/ijms24087055. Epub 2023 Apr 11
[PubMed PMID: 37108218]
[44]
Eldridge GR, Hughey H, Rosenberger L, Martin SM, Shapiro AM, D'Antonio E, Krejci KG, Shore N, Peterson J, Lukes AS, Starks CM. Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study. Human vaccines & immunotherapeutics. 2021 May 4:17(5):1262-1270. doi: 10.1080/21645515.2020.1834807. Epub 2020 Dec 16
[PubMed PMID: 33325785]
[45]
Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Fonck VG. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. The Lancet. Infectious diseases. 2017 May:17(5):528-537. doi: 10.1016/S1473-3099(17)30108-1. Epub 2017 Feb 24
[PubMed PMID: 28238601]
Level 1 (high-level) evidence
[46]
Prattley S, Geraghty R, Moore M, Somani BK. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. European urology focus. 2020 May 15:6(3):593-604. doi: 10.1016/j.euf.2019.11.002. Epub 2019 Dec 2
[PubMed PMID: 31806578]
Level 1 (high-level) evidence
[47]
Benito-Villalvilla C, Cirauqui C, Diez-Rivero CM, Casanovas M, Subiza JL, Palomares O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal immunology. 2017 Jul:10(4):924-935. doi: 10.1038/mi.2016.112. Epub 2016 Dec 14
[PubMed PMID: 27966556]
[48]
Kovacic J, Canagasingham A, Zhong W, Lockhart K, Dhar A, Shepherd A, Chung A. Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double-blind randomized controlled trial protocol. BJU international. 2024 Apr:133 Suppl 4():37-43. doi: 10.1111/bju.16247. Epub 2023 Dec 26
[PubMed PMID: 38060333]
Level 1 (high-level) evidence
[49]
Gupta K, Hooton TM, Roberts PL, Stamm WE. Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women. Annals of internal medicine. 2001 Jul 3:135(1):9-16
[PubMed PMID: 11434727]
[50]
Ramírez-Sevilla C, Gómez-Lanza E, Llopis-Manzanera J, Cetina-Herrando A, Puyol-Pallàs JM. Effectiveness and health cost analysis between immunoprophylaxis with MV140 autovaccine, MV140 vaccine and continuous treatment with antibiotics to prevent recurrent urinary tract infections. Actas urologicas espanolas. 2023 Jan-Feb:47(1):27-33. doi: 10.1016/j.acuroe.2022.08.016. Epub 2022 Aug 12
[PubMed PMID: 36470711]
[51]
. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM evidence. 2022 May:1(5):EVIDx2200081. doi: 10.1056/EVIDx2200081. Epub 2022 Mar 7
[PubMed PMID: 38319208]
[52]
Nickel JC, Doiron RC. An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women. Pathogens (Basel, Switzerland). 2023 Feb 21:12(3):. doi: 10.3390/pathogens12030359. Epub 2023 Feb 21
[PubMed PMID: 36986281]
[53]
Lorenzo-Gómez MF, Foley S, Nickel JC, García-Cenador MB, Padilla-Fernández BY, González-Casado I, Martínez-Huélamo M, Yang B, Blick C, Ferreira F, Caballero R, Saz-Leal P, Casanovas M. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM evidence. 2022 Apr:1(4):EVIDoa2100018. doi: 10.1056/EVIDoa2100018. Epub 2022 Jan 21
[PubMed PMID: 38319200]
[54]
Saz-Leal P, Ligon MM, Diez-Rivero CM, García-Ayuso D, Mohanty S, Conejero L, Brauner A, Subiza JL, Mysorekar IU. MV140 mucosal bacterial vaccine improves uropathogenic E. coli clearance in an experimental model of urinary tract infection. Research square. 2023 Jun 7:():. pii: rs.3.rs-2992611. doi: 10.21203/rs.3.rs-2992611/v1. Epub 2023 Jun 7
[PubMed PMID: 37333312]
[55]
Martín-Cruz L, Angelina A, Baydemir I, Bulut Ö, Subiza JL, Netea MG, Domínguez-Andrés J, Palomares O. Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections. Frontiers in immunology. 2022:13():1066383. doi: 10.3389/fimmu.2022.1066383. Epub 2022 Nov 24
[PubMed PMID: 36505433]
[56]
Zare M, Vehreschild MJGT, Wagenlehner F. Management of uncomplicated recurrent urinary tract infections. BJU international. 2022 Jun:129(6):668-678. doi: 10.1111/bju.15630. Epub 2021 Nov 17
[PubMed PMID: 34741796]
[57]
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. The Cochrane database of systematic reviews. 2004:2004(3):CD001209
[PubMed PMID: 15266443]
Level 1 (high-level) evidence
[58]
Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations. The Journal of urology. 2018 Dec:200(6):1174-1191. doi: 10.1016/j.juro.2018.04.088. Epub 2018 Jun 22
[PubMed PMID: 29940246]
[59]
Al-Badr A, Al-Shaikh G. Recurrent Urinary Tract Infections Management in Women: A review. Sultan Qaboos University medical journal. 2013 Aug:13(3):359-67
[PubMed PMID: 23984019]
[60]
Taich L, Zhao H, Cordero C, Anger JT. New paradigms in the management of recurrent urinary tract infections. Current opinion in urology. 2020 Nov:30(6):833-837. doi: 10.1097/MOU.0000000000000823. Epub
[PubMed PMID: 32941258]
Level 3 (low-level) evidence
[61]
Marschall J, Carpenter CR, Fowler S, Trautner BW, CDC Prevention Epicenters Program. Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis. BMJ (Clinical research ed.). 2013 Jun 11:346():f3147. doi: 10.1136/bmj.f3147. Epub 2013 Jun 11
[PubMed PMID: 23757735]
Level 1 (high-level) evidence
[62]
Fisher H, Oluboyede Y, Chadwick T, Abdel-Fattah M, Brennand C, Fader M, Harrison S, Hilton P, Larcombe J, Little P, McClurg D, McColl E, N'Dow J, Ternent L, Thiruchelvam N, Timoney A, Vale L, Walton K, von Wilamowitz-Moellendorff A, Wilkinson J, Wood R, Pickard R. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial. The Lancet. Infectious diseases. 2018 Sep:18(9):957-968. doi: 10.1016/S1473-3099(18)30279-2. Epub 2018 Jun 28
[PubMed PMID: 30037647]
Level 1 (high-level) evidence
[63]
Scherberich JE, Fünfstück R, Naber KG. Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatment. GMS infectious diseases. 2021:9():Doc07. doi: 10.3205/id000076. Epub 2021 Dec 21
[PubMed PMID: 35106269]
[65]
Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA internal medicine. 2018 Nov 1:178(11):1509-1515. doi: 10.1001/jamainternmed.2018.4204. Epub
[PubMed PMID: 30285042]
Level 1 (high-level) evidence
[66]
Al Demour S, Ababneh MA. Evaluation of Behavioral and Susceptibility Patterns in Premenopausal Women with Recurrent Urinary Tract Infections: A Case Control Study. Urologia internationalis. 2018:100(1):31-36. doi: 10.1159/000485568. Epub 2017 Dec 14
[PubMed PMID: 29241191]
Level 2 (mid-level) evidence
[67]
Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. The Cochrane database of systematic reviews. 2012 Oct 17:10(10):CD001321. doi: 10.1002/14651858.CD001321.pub5. Epub 2012 Oct 17
[PubMed PMID: 23076891]
Level 1 (high-level) evidence
[68]
Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. The Journal of urology. 2003 Sep:170(3):867-9
[PubMed PMID: 12913718]
Level 1 (high-level) evidence
[69]
Hopkins WJ, Elkahwaji J, Beierle LM, Leverson GE, Uehling DT. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. The Journal of urology. 2007 Apr:177(4):1349-53; quiz 1591
[PubMed PMID: 17382730]
Level 1 (high-level) evidence
[70]
Sánchez-Ramón S, Fernández-Paredes L, Saz-Leal P, Diez-Rivero CM, Ochoa-Grullón J, Morado C, Macarrón P, Martínez C, Villaverde V, de la Peña AR, Conejero L, Hernández-Llano K, Cordero G, Fernández-Arquero M, Gutierrez BF, Candelas G. Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment. Frontiers in immunology. 2021:12():675735. doi: 10.3389/fimmu.2021.675735. Epub 2021 Jun 4
[PubMed PMID: 34149711]
[71]
Spaulding CN, Klein RD, Schreiber HL 4th, Janetka JW, Hultgren SJ. Precision antimicrobial therapeutics: the path of least resistance? NPJ biofilms and microbiomes. 2018:4():4. doi: 10.1038/s41522-018-0048-3. Epub 2018 Feb 27
[PubMed PMID: 29507749]
[72]
Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. The Journal of urology. 2013 Dec:190(6):1981-9. doi: 10.1016/j.juro.2013.04.142. Epub 2013 Jul 15
[PubMed PMID: 23867306]
Level 1 (high-level) evidence
[73]
Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, Stappenbeck TS, Hansson GC, Stenson WF, Colonna M, Stapleton AE, Hultgren SJ. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine. 2014 Nov:1(1):46-57. doi: 10.1016/j.ebiom.2014.10.011. Epub 2014 Oct 24
[PubMed PMID: 26125048]
[74]
Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ (Clinical research ed.). 2015 Dec 23:351():h6544. doi: 10.1136/bmj.h6544. Epub 2015 Dec 23
[PubMed PMID: 26698878]
Level 1 (high-level) evidence
[75]
Platt FW, Keating KN. Differences in physician and patient perceptions of uncomplicated UTI symptom severity: understanding the communication gap. International journal of clinical practice. 2007 Feb:61(2):303-8
[PubMed PMID: 17263717]
Level 3 (low-level) evidence
[76]
Pasay DK, Guirguis MS, Shkrobot RC, Slobodan JP, Wagg AS, Sadowski CA, Conly JM, Saxinger LM, Bresee LC. Antimicrobial stewardship in rural nursing homes: Impact of interprofessional education and clinical decision tool implementation on urinary tract infection treatment in a cluster randomized trial. Infection control and hospital epidemiology. 2019 Apr:40(4):432-437. doi: 10.1017/ice.2019.9. Epub 2019 Feb 20
[PubMed PMID: 30782227]
Level 1 (high-level) evidence